Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet

Acta Pharmacologica Sinica

Volumn 30, Issue 11, 2009, Pages 1505-1512

  Guo, Hong Xia ^a   Liu, Dai Hua ^a   Ma, Ying ^a   Liu, Jin Feng ^a   Wang, Ying ^a   Du, Zhi Yan ^a   Wang, Xin ^a   Shen, Jing Kang ^a   Peng, Hong Li ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

AMPK; Baicalin; Hepatic steatosis; Tumor necrosis factor

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; BAICALIN; CHOLESTEROL; FATTY ACID; FATTY ACID SYNTHASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BODY WEIGHT; CELL STRAIN HEPG2; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME PHOSPHORYLATION; FATTY LIVER; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; INTRAABDOMINAL FAT; LIPID DIET; LIPID STORAGE; LIPOGENESIS; LIVER HISTOLOGY; LONG TERM CARE; MALE; METABOLIC DISORDER; NONHUMAN; OBESITY; RAT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FATTY LIVER; FLAVONOIDS; HEP G2 CELLS; HUMANS; MALE; METABOLIC DISEASES; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SCUTELLARIA BAICALENSIS; WEIGHT GAIN;

EID: 70449370069     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.150     Document Type: Article

References (37)

1. Boden G. Obesity and free fatty acids. Endocrinol Metab Clin North Am 2008; 37: 635-646
2. Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004; 5: 27-42.
3. Akbar DH, Kawther AH. Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we don't know. Med Sci Monit 2006; 12: RA23-RA26.
4. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289: 3000-3004
5. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-589
6. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905.
7. Younossi ZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 28: 2-12.
8. Marcaurelle LA, Johannes CW. Application of natural product-inspired diversity-oriented synthesis to drug discovery. Prog Drug Res 2008; 66: 189-216.
9. Lin CL, Huang HC, Lin JK. Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. J Lipid Res 2007; 48: 2334-2343
10. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006; 55: 2180-2191
11. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-342
12. Yu X, McCorkle S, Wang M, Lee Y, Li J, Saha AK, et al. Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. Diabetologia 2004; 47: 2012-2021
13. Song Z, Deaciuc I, Zhou Z, Song M, Chen T, Hill D, et al. Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis. Am J Physiol Gastrointest Liver Physiol 2007; 293: G894-G902.
14. Park KG, Min AK, Koh EH, Kim HS, Kim MO, Park HS, et al. Alphalipoic acid decreases hepatic lipogenesis through adenosine monophosphate- activated protein kinase (AMPK)-dependent and AMPKindependent pathways. Hepatology 2008; 48: 1477-1486
15. Yang J, Maika S, Craddock L, King JA, Liu ZM. Chronic activation of AMP-activated protein kinase-alpha1 in liver leads to decreased adiposity in mice. Biochem Biophys Res Commun 2008; 370: 248-253
16. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174
17. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52: 1364-1370
18. Huang WH, Lee AR, Yang CH. Antioxidative and anti-inflammatory activities of polyhydroxyflavonoids of Scutellaria baicalensis GEORGI. Biosci Biotechnol Biochem 2006; 70: 2371-2380
19. Waisundara VY, Hsu A, Huang D, Tan BK. Scutellaria baicalensis enhances the anti-diabetic activity of metformin in streptozotocininduced diabetic Wistar rats. Am J Chin Med 2008; 36: 517-540
20. Regulska-Ilow B, Biernat J, Grajeta H, Ilow R, Drzewicka M. Influence of bioflavonoids from the radix extract of Scutellaria baicalensis on the level of serum lipids, and the development of laboratory rats fed with fresh and oxidized fats. Nahrung 2004; 48: 123-128
21. Sekiya N, Kogure T, Kita T, Kasahara Y, Sakakibara I, Goto H, et al. Reduction of plasma triglyceride level and enhancement of plasma albumin concentration by Oren-gedoku-to administration. Phytomedicine 2002; 9: 455-460
22. Sekiya N, Kainuma M, Hikiami H, Nakagawa T, Kouta K, Shibahara N, et al. Oren-gedoku-to and Keishi-bukuryo-gan-ryo inhibit the progression of atherosclerosis in diet-induced hypercholesterolemic rabbits. Biol Pharm Bull 2005; 28: 294-298
23. Fujimoto M, Tsuneyama K, Kainuma M, Sekiya N, Goto H, Takano Y, et al. Evidence-based efficacy of Kampo formulas in a model of non alcoholic fatty liver. Exp Biol Med (Maywood ) 2008; 233: 328-337
24. Heider JG, Boyett RL. The picomole determination of free and total cholesterol in cells in culture. J Lipid Res 1978; 19: 514-518
25. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007; 8: 774-785
26. Caldwell SH, Argo CK, Al-Osaimi AM. Therapy of NAFLD: insulin sensitizing agents. J Clin Gastroenterol 2006; 40 Suppl 1: S61-S66.
27. Shimano H, Yahagi N, memiya-Kudo M, Hasty AH, Osuga J, Tamura Y, et al. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem 1999; 274: 35832-35839
28. Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem 2004; 279: 47898-47905
29. Chang CP, Huang WT, Cheng BC, Hsu CC, Lin MT. The flavonoid baicalin protects against cerebrovascular dysfunction and brain inflammation in experimental heatstroke. Neuropharmacology 2007; 52: 1024-1033
30. Kim DH, Kim HK, Park S, Kim JY, Zou Y, Cho KH, et al. Short-term feeding of baicalin inhibits age-associated NF-kappaB activation. Mech Ageing Dev 2006; 127: 719-725
31. Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig Liver Dis 2007; 39: 293-304.
32. Viollet B, Foretz M, Guigas B, Horman S, Dentin R, Bertrand L, et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 2006; 574: 41-53.
33. Misra P. AMP activated protein kinase: a next generation target for total metabolic control. Expert Opin Ther Targets 2008; 12: 91-100.
34. Hardie DG. The AMP-activated protein kinase pathway--new players upstream and downstream. J Cell Sci 2004; 117: 5479-5487
35. Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology 2008; 48: 770-781
36. Steinberg GR. Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance. Cell Cycle 2007; 6: 888-894
37. Wan JY, Gong X, Zhang L, Li HZ, Zhou YF, Zhou QX. Protective effect of baicalin against lipopolysaccharide/D-galactosamine-induced liver injury in mice by up-regulation of heme oxygenase-1. Eur J Pharmacol 2008; 587: 302-308